-
1
-
-
56749106312
-
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein
-
Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-2207
-
(2008)
N Engl J Med
, vol.359
, pp. 2195-2207
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.3
Genest, J.4
Gotto Jr., A.M.5
Kastelein, J.J.6
-
2
-
-
63649095045
-
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
-
Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM, Kastelein JJP, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-1182
-
(2009)
Lancet
, vol.373
, pp. 1175-1182
-
-
Ridker, P.M.1
Danielson, E.2
Fonseca, F.A.H.3
Genest, J.4
Gotto, A.M.5
Kastelein, J.J.P.6
-
3
-
-
70350360003
-
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations
-
Genest J, McPherson R, Frohlich J, Anderson T, Campbell N, Carpentier A, et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009;25:567-579
-
(2009)
Can J Cardiol
, vol.25
, pp. 567-579
-
-
Genest, J.1
McPherson, R.2
Frohlich, J.3
Anderson, T.4
Campbell, N.5
Carpentier, A.6
-
4
-
-
71649114494
-
Clinical implications of JUPITER (Justification for the Use of statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) in a U.S. population: Insights from the ARIC (Atherosclerosis Risk in Communities) Study
-
Yang EY, Nambi V, Tang Z, Virani SS, Boerwinkle E, Hoogeveen RC, et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a U.S. population: insights from the ARIC (Atherosclerosis Risk in Communities) Study. J Am Col Cardiol 2009;54: 2388-2395
-
(2009)
J Am Col Cardiol
, vol.54
, pp. 2388-2395
-
-
Yang, E.Y.1
Nambi, V.2
Tang, Z.3
Virani, S.S.4
Boerwinkle, E.5
Hoogeveen, R.C.6
-
5
-
-
0035963529
-
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
-
DOI 10.1056/NEJM200106283442601
-
Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001;344: 1959-1965 (Pubitemid 32568149)
-
(2001)
New England Journal of Medicine
, vol.344
, Issue.26
, pp. 1959-1965
-
-
Ridker, P.M.1
Rifai, N.2
Clearfield, M.3
Downs, J.R.4
Weis, S.E.5
Miles, J.S.6
Gotto Jr., A.M.7
-
6
-
-
70349493143
-
Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)
-
for the CORONA Study Group
-
McMurray JJV, Kjekshus J, Gullestad L, Dunselman P, Hjalmarson A, Wedel H, et al., for the CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation 2009;120:2188-2196
-
(2009)
Circulation
, vol.120
, pp. 2188-2196
-
-
McMurray, J.J.V.1
Kjekshus, J.2
Gullestad, L.3
Dunselman, P.4
Hjalmarson, A.5
Wedel, H.6
|